The drug was invented in Scotland in the 1970s, and has been given away for free by Jacobus pharmaceuticals for 20 years. One need only look at this case to see why medical price caps are essential. Neither individuals nor insurance companies nor the US taxpayer can afford US medical charges. The Canadian system works only because of caps on charges, and not just drug charges. US doctors are gouging too.
The $375,000 would even take a big chunk out of the Catalyst CEO, Patrick J McEnany,’s $900.000 salary. US Senator Sanders explains: “Recently, Catalyst licensed the rights to the drug and received exclusive rights to market Firdapse for seven years under the FDA’s orphan drug designation. In December 2018, Catalyst announced to investors it would set the list price for Firdapse at $375,000 per year”
Catalyst was sued by investors in 2013 for failure to disclose the…
View original post 806 more words